Literature DB >> 29501276

Surgical timing of anterior cruciate ligament reconstruction to prevent associated meniscal and cartilage lesions.

Shuji Taketomi1, Hiroshi Inui2, Ryota Yamagami2, Kohei Kawaguchi2, Keiu Nakazato2, Kenichi Kono2, Manabu Kawata2, Takumi Nakagawa3, Sakae Tanaka2.   

Abstract

BACKGROUND: The purpose of this study was to analyze the association between the prevalence of meniscal and chondral lesions and the timing of surgery in patients undergoing primary anterior cruciate ligament (ACL) reconstruction to determine a safe time for surgery.
METHODS: This retrospective study involved 226 patients (91 females and 135 males; median age, 29 years) undergoing primary ACL reconstruction. Time interval from ACL injury to surgery (median, 4 months; range, 1-420 months) and concomitant meniscal and cartilage lesions in ACL reconstruction were reviewed. Receiver operating characteristic (ROC) curve analysis was used to determine the precise threshold interval to surgery to prevent meniscal or cartilage lesions. The risk of lesion occurrence after each cutoff period was determined using odds ratio (OR).
RESULTS: The incidences of medial meniscus (MM), lateral meniscus (LM), and cartilage lesions were 43.8%, 32.7%, and 27.4%, respectively. ROC analysis revealed that patients who waited for more than 6, 4, and 5 months for ACL reconstruction had a significantly greater risk of associated MM, LM, and chondral lesions, respectively. Patients who underwent ACL reconstruction ≥7 months after injury had OR of 4.1 (p < 0.001) for the presence of MM lesion as compared with those who underwent reconstruction within 6 months. Similarly, patients who underwent ACL reconstruction ≥5 months after injury had OR of 1.9 (p = 0.023) for the presence of LM lesion as compared with those who underwent reconstruction within 4 months, and patients who underwent ACL reconstruction ≥6 months after injury had OR of 2.9 (p < 0.001) for chondral lesion as compared with those who underwent reconstruction within 6 months.
CONCLUSION: ACL reconstruction should be performed within approximately 6 months after the injury to prevent associated meniscal or chondral lesions.
Copyright © 2018 The Japanese Orthopaedic Association. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29501276     DOI: 10.1016/j.jos.2018.02.006

Source DB:  PubMed          Journal:  J Orthop Sci        ISSN: 0949-2658            Impact factor:   1.601


  6 in total

1.  Prevalence of concomitant knee injuries associated with anterior cruciate ligament tear in kabaddi and football players.

Authors:  Ravi Gupta; Anil Kapoor; Gladson DavidMasih
Journal:  J Clin Orthop Trauma       Date:  2020-06-06

2.  Acute ACL reconstruction shows superior clinical results and can be performed safely without an increased risk of developing arthrofibrosis.

Authors:  Christoffer von Essen; Karl Eriksson; Björn Barenius
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2019-09-26       Impact factor: 4.342

3.  Anterior cruciate ligament reconstruction-related patient injuries: a nationwide registry study in Finland.

Authors:  Kirsi-Maaria Nyrhinen; Ville Bister; Teemu Helkamaa; Arne Schlenzka; Henrik Sandelin; Jerker Sandelin; Arsi Harilainen
Journal:  Acta Orthop       Date:  2019-10-15       Impact factor: 3.717

4.  The predictive factors that are associated with the number of sutures used during meniscal repair.

Authors:  Xiaoxiao Song; Dongyang Chen; Xinsheng Qi; Qing Jiang; Caiwei Xia
Journal:  BMC Musculoskelet Disord       Date:  2021-01-12       Impact factor: 2.362

5.  Meniscus repair with simultaneous anterior cruciate ligament reconstruction: Clinical outcomes, failure rates and subsequent processing.

Authors:  Yu-Ping Yang; Xiao Ma; Hua An; Xiao-Peng Liu; Ning An; Ying-Fang Ao
Journal:  Chin J Traumatol       Date:  2021-09-20

Review 6.  Risk factors of cartilage lesion after anterior cruciate ligament reconstruction.

Authors:  Zirong Huang; Jiaming Cui; Mingjin Zhong; Zhenhan Deng; Kang Chen; Weimin Zhu
Journal:  Front Cell Dev Biol       Date:  2022-09-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.